For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Nootropic & Cognitive · Comparison

Dihexa vs Leucine Enkephalin (Leu-Enkephalin)

A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

DihexaLeucine Enkephalin (Leu-Enkephalin)
CategoryNootropic & CognitiveNootropic & Cognitive
Also known asPNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amideLeu5-enkephalin, YGGFL, L-enkephalin, endogenous opioid pentapeptide
EvidencePreclinical onlyResearch-stage
Dosing range10mg–20mg mg, Once daily (or every other day — long-lasting effects)0.1mg–1mg mg, Intranasal or SC; extremely short half-life requires frequent dosing or continuous delivery
AdministrationOral (capsule), Transdermal (cream/lotion — lipophilicity makes this effective), Subcutaneous injection (less common)Intranasal, Subcutaneous injection, Intraventricular (research only)
Key side effectsPotential for pro-proliferative effects — HGF/c-Met pathway promotes cell growth (theoretical cancer concern at high doses), Headache (uncommon), Mental fatigue if overdosed, Long half-life means effects accumulate — take every other day initiallyTolerance development with repeated use (opioid receptor class effect), Mild euphoria (δ-opioid mediated), Nausea (at high doses), Constipation (opioid class effect at high doses)
Cited sources2 references2 references

Key differences

  • Evidence level differs: Dihexa is preclinical only, while Leucine Enkephalin (Leu-Enkephalin) is research-stage.
  • Administration: Dihexa — Oral (capsule), Transdermal (cream/lotion — lipophilicity makes this effective), Subcutaneous injection (less common); Leucine Enkephalin (Leu-Enkephalin) — Intranasal, Subcutaneous injection, Intraventricular (research only).
  • Frequency: Dihexa is typically Once daily (or every other day — long-lasting effects); Leucine Enkephalin (Leu-Enkephalin) is Intranasal or SC; extremely short half-life requires frequent dosing or continuous delivery.

How each works

Dihexa

Dihexa (PNB-0408) was developed by Joseph Harding and colleagues at WSU as a metabolically stable angiotensin IV analog. It binds hepatocyte growth factor (HGF), potentiating its interaction with the c-Met receptor — a pathway critical for dendritic branching, synapse formation, and synaptic plasticity. In rodent Alzheimer's and scopolamine-impaired models, Dihexa restored cognitive performance at doses ~7 orders of magnitude lower than BDNF. It readily crosses the blood-brain barrier due to its lipophilicity, unlike BDNF itself.

Leucine Enkephalin (Leu-Enkephalin)

Leu-enkephalin was one of the first endogenous opioid peptides characterized, following the discovery of opioid receptors in 1973. It preferentially activates δ-opioid receptors (DOR) over μ-opioid receptors (MOR), producing analgesia, modulation of GABA release, and reward pathway activation. Enkephalinase (neprilysin/NEP, CD10) cleaves the Gly-Phe bond within ~2 minutes IV, necessitating stable analogues or NEP inhibitors for research applications.

Read the full Dihexa profileRead the full Leucine Enkephalin (Leu-Enkephalin) profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.